Brookwood Investment Group LLC Purchases 7,138 Shares of Boston Scientific Corporation $BSX

Brookwood Investment Group LLC increased its position in Boston Scientific Corporation (NYSE:BSX) by 119.9% during the third quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 13,092 shares of the medical equipment provider’s stock after purchasing an additional 7,138 shares during the quarter. Brookwood Investment Group LLC’s holdings in Boston Scientific were worth $1,278,000 as of its most recent SEC filing.

Several other hedge funds have also bought and sold shares of BSX. Steph & Co. bought a new stake in Boston Scientific in the third quarter valued at approximately $25,000. Financial Consulate Inc. acquired a new position in shares of Boston Scientific during the 3rd quarter worth approximately $25,000. FWL Investment Management LLC acquired a new position in shares of Boston Scientific during the 2nd quarter worth approximately $26,000. Sound Income Strategies LLC raised its stake in Boston Scientific by 90.9% in the 2nd quarter. Sound Income Strategies LLC now owns 252 shares of the medical equipment provider’s stock valued at $27,000 after acquiring an additional 120 shares during the period. Finally, Kilter Group LLC acquired a new stake in Boston Scientific during the 2nd quarter valued at $30,000. 89.07% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling

In other Boston Scientific news, EVP Arthur C. Butcher sold 17,313 shares of the firm’s stock in a transaction dated Monday, December 1st. The shares were sold at an average price of $101.55, for a total value of $1,758,135.15. Following the transaction, the executive vice president directly owned 23,600 shares of the company’s stock, valued at $2,396,580. This trade represents a 42.32% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, EVP Joseph Michael Fitzgerald sold 50,000 shares of the business’s stock in a transaction that occurred on Monday, November 3rd. The shares were sold at an average price of $99.47, for a total transaction of $4,973,500.00. Following the completion of the transaction, the executive vice president owned 178,342 shares of the company’s stock, valued at $17,739,678.74. The trade was a 21.90% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold 93,095 shares of company stock valued at $9,305,450 over the last quarter. 0.50% of the stock is owned by company insiders.

Boston Scientific Stock Down 0.7%

NYSE BSX opened at $94.72 on Friday. The company has a current ratio of 1.51, a quick ratio of 0.96 and a debt-to-equity ratio of 0.47. The company has a market cap of $140.42 billion, a price-to-earnings ratio of 50.65, a PEG ratio of 1.69 and a beta of 0.67. The company has a 50 day moving average of $97.92 and a 200-day moving average of $100.92. Boston Scientific Corporation has a 1-year low of $85.98 and a 1-year high of $109.50.

Boston Scientific (NYSE:BSX) last issued its quarterly earnings results on Wednesday, October 22nd. The medical equipment provider reported $0.75 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.71 by $0.04. The business had revenue of $5.07 billion for the quarter, compared to the consensus estimate of $4.97 billion. Boston Scientific had a return on equity of 19.46% and a net margin of 14.43%.The firm’s quarterly revenue was up 20.3% compared to the same quarter last year. During the same quarter in the prior year, the business posted $0.63 earnings per share. Boston Scientific has set its FY 2025 guidance at 3.020-3.040 EPS and its Q4 2025 guidance at 0.770-0.790 EPS. On average, equities research analysts expect that Boston Scientific Corporation will post 2.85 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several research firms have commented on BSX. Weiss Ratings reiterated a “buy (b-)” rating on shares of Boston Scientific in a report on Wednesday, October 8th. Wall Street Zen lowered shares of Boston Scientific from a “buy” rating to a “hold” rating in a research note on Saturday, December 20th. Evercore ISI restated an “outperform” rating on shares of Boston Scientific in a research report on Wednesday, October 22nd. Cowen reaffirmed a “buy” rating on shares of Boston Scientific in a research report on Thursday, December 11th. Finally, Morgan Stanley increased their target price on Boston Scientific from $125.00 to $130.00 and gave the stock an “overweight” rating in a research note on Thursday, October 23rd. Two investment analysts have rated the stock with a Strong Buy rating, twenty have issued a Buy rating and two have assigned a Hold rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Buy” and a consensus price target of $124.85.

About Boston Scientific

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.